NHGRI logo
Program Director

Division of Genomics and Society

Pronouns

She/her/hers

Education

Ph. D. Johns Hopkins University

B.S. University of Virginia

B.A. University of Virginia

Biography

Dr. Sheethal Jose joined National Human Genome Research Institute (NHGRI) in January 2024 as a program director in the Division of Genomics and Society. She oversees a portfolio of research and career development grants related to the ethical, legal, and social implications (ELSI) of genomic research. Currently, Dr. Jose focuses on ELSI Research Program grants and initiatives related to Genomics and Sociocultural Structures and Values. She also participates in the Developmental Genotype-Tissue Expression (dGTEx) project.

Prior to joining as a program director, Dr. Jose was working on her doctoral dissertation at the Johns Hopkins Center for Bridging Infectious Disease, Genomics, and Society (BRIDGES) which is a Center for Excellence in ELSI Research (CEER) supported by NHGRI. Her dissertation was focused on exploring health professionals’ perspectives on the ethical acceptability of using host genomic information in the clinical care and public health control of COVID-19; and understanding its impact on concerns of genetic determinism and biologization of race using both empirical and normative approaches. She also worked at NHGRI for 3 years as a scientific program analyst on the Electronic Medical Records and Genomics (eMERGE) Network and the Knockout Mouse Program (KOMP)/International Mouse Phenotyping Consortium (IMPC).

Dr. Jose received a B.S. in Biology and a B.A. in Political Science from the University of Virginia and a Ph.D. in Bioethics and Health Policy from the Johns Hopkins Bloomberg School of Public Health and the Berman Institute of Bioethics.

Visit the ELSI Research Areas webpage for more information on areas of ELSI research.

Publications

Jose S, Bollinger J, Geller G, Greene J, Henry LM, Hutler B, Juengst ET, Kahn J, Mastroianni A, Mooney G, White A, Wilbanks R, Mathews D. Blurring Boundaries: A Proposed Research Agenda for Ethical, Legal, Social, and Historical Studies at the Intersection of Infectious and Genetic Disease. Journal of Law, Medicine, and Ethics. 2024. (in-press)

Jose S, Geller G, Bollinger J, Mathews D, Kahn J, Garibaldi B. The Ethics of Using COVID-19 Host Genomic Information for Clinical and Public Health Decision-making during the Pandemic: A Survey of US Health Professionals. Human Genetics and Genomics Advances. 2023; 5(1), 100255.

Linder JE, Tao R, Chung WK, Kiryluk K, Liu C, Weng C, Connolly JJ, Hakonarson H, Harr M, Leppig KA, Jarvik GP, Veenstra DL, Aufox S, Chisholm RL, Gordon AS, Hoell C, Rasmussen-Torvik LJ, Smith ME, Holm IA, Miller EM, Prows CA, Elskeally O, Kullo IJ, Lee C, Jose S, Manolio TA, Rowley R, Padi-Adjirackor NA, Wilmayani NK, City B, Wei WQ, Wiesner GL, Rahm AK, Williams JL, Williams MS, Peterson JF. Prospective, multi-site study of healthcare utilization after actionable monogenic findings from clinical sequencing. American Journal of Human Genetics. 2023; 110(11), 1950-1958.

eMERGE Consortium [including Jose S]. Lessons learned from the eMERGE Network: balancing genomics in discovery and practice. Human Genetics and Genomics Advances. 2021; 2(1), 100018.

eMERGE Consortium [including Jose S]. Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics. 2019; 105(3), 588.

Stremska, ME, Dai C, Venkatadri R, Wang H, Sabapathy V, Kumar G, Jose S, Mohammad S, Sung SJ, Fu SM, Sharma R. IL233, an IL-2-IL-33 Hybrid Cytokine Induces Prolonged Remission of Mouse Lupus Nephritis by Targeting Treg Cells as a Single Therapeutic Agent. Journal of Autoimmunity. 2019; 102, 133–141.

Kullo IJ, [and 26 others, including Jose S]. The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results. Mayo Clinic Proceedings. 2018; 93(11), 1600-1610.

Stremska ME, Jose S, Sabapathy V, Huang L, Bajwa A, Kinsey GR, Sharma PR, Mohammad S, Rosin DL, Okusa MD, Sharma R. IL233, a Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury. Journal of the American Society of Nephrology. 2017; 28(9), 2681-2693.

Last updated: March 28, 2024